Winst gevend schreef op 24 maart 2023 21:06:
Pharming, which acquired global rights to Joenja from Novartis in 2019,
declined to comment on the pricing and said it would provide more details on Monday.
At least two analysts expected the drug to be priced at as much as $400,000.
Oppenheimer analyst Hartaj Singh expected Joenja to be priced between $250,000 and $400,000,
and forecast peak sales of $200 million to $300 million, ahead of the approval.